Unicycive Therapeutics, Inc.
UNCY
$5.86
-$0.14-2.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.56% | 105.80% | 143.23% | 91.01% | 24.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.45% | -5.92% | -13.21% | 46.70% | 5.27% |
| Operating Income | -17.45% | 5.92% | 13.21% | -46.70% | -5.27% |
| Income Before Tax | -46.75% | -165.42% | 102.72% | -176.03% | 5.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.75% | -165.42% | 102.72% | -176.03% | 5.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.75% | -165.42% | 102.72% | -176.03% | 5.47% |
| EBIT | -17.45% | 5.92% | 13.21% | -46.70% | -5.27% |
| EBITDA | -17.41% | 6.00% | 13.21% | -46.66% | -5.21% |
| EPS Basic | 27.75% | -113.34% | 100.56% | 8.99% | 65.89% |
| Normalized Basic EPS | 27.73% | -120.16% | 100.81% | 8.99% | 65.32% |
| EPS Diluted | 27.75% | 64.20% | 93.54% | 8.99% | 65.89% |
| Normalized Diluted EPS | 27.73% | -150.01% | 100.77% | 8.99% | 65.32% |
| Average Basic Shares Outstanding | 103.11% | 224.47% | 234.91% | 203.29% | 172.56% |
| Average Diluted Shares Outstanding | 103.11% | 30.80% | 255.02% | 203.29% | 172.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |